Your browser doesn't support javascript.
loading
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Moodie, Zoe; Walsh, Stephen R; Laher, Fatima; Maganga, Lucas; Herce, Michael E; Naidoo, Sarita; Hosseinipour, Mina C; Innes, Craig; Bekker, Linda-Gail; Grunenberg, Nicole; Mann, Philipp; Yu, Chenchen; deCamp, Allan C; Miner, Maurine D; Yates, Nicole L; Heptinstall, Jack; Mkhize, Nonhlanhla N; Dintwe, One; Frahm, Nicole; Cohen, Kristen W; Allen, Mary; Hutter, Julia; Wagner, Ralf; Pantaleo, Giuseppe; McElrath, M Juliana; Tomaras, Georgia D; Morris, Lynn; Montefiori, David C; Andersen-Nissen, Erica; Gray, Glenda E; Gilbert, Peter B; Kublin, James G.
Afiliación
  • Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Walsh SR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
  • Laher F; Harvard Medical School, Boston, Massachusetts, United States of America.
  • Maganga L; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
  • Herce ME; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
  • Naidoo S; NIMR-Mbeya Medical Research Center, Mbeya, Tanzania.
  • Hosseinipour MC; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Innes C; HIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa.
  • Bekker LG; UNC Project Malawi, Lilongwe, Malawi.
  • Grunenberg N; Aurum Institute, Klerksdorp, South Africa.
  • Mann P; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
  • Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • deCamp AC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Miner MD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Yates NL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Heptinstall J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Mkhize NN; Duke Human Vaccine Institute, Department of Surgery Duke University, Durham, North Carolina, United States of America.
  • Dintwe O; Duke Human Vaccine Institute, Department of Surgery Duke University, Durham, North Carolina, United States of America.
  • Frahm N; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
  • Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Allen M; Cape Town HVTN Immunology Laboratory, Hutchinson Center Research Institute of South Africa, Cape Town, South Africa.
  • Hutter J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Wagner R; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Pantaleo G; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland United States of America.
  • McElrath MJ; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland United States of America.
  • Tomaras GD; Institute of Medical Microbiology and Hygiene, University of Regensberg, Regensberg, Germany.
  • Morris L; Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
  • Montefiori DC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Andersen-Nissen E; Duke Human Vaccine Institute, Department of Surgery Duke University, Durham, North Carolina, United States of America.
  • Gray GE; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
  • Gilbert PB; Duke Human Vaccine Institute, Department of Surgery Duke University, Durham, North Carolina, United States of America.
  • Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
PLoS Med ; 17(5): e1003117, 2020 05.
Article en En | MEDLINE | ID: mdl-32442195
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Vacunas contra el SIDA / Anticuerpos Neutralizantes Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: PLoS Med Asunto de la revista: MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Vacunas contra el SIDA / Anticuerpos Neutralizantes Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: PLoS Med Asunto de la revista: MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos